Cardiovascular Systems Signs U.S. Distribution Agreement with Asahi Intecc Co., Ltd.

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, has signed an exclusive distribution agreement with Asahi Intecc Co., Ltd., based in Japan, to market its peripheral guide wire line in the United States.

“The addition of Asahi guide wires expands our product portfolio and reinforces our leadership position in the peripheral arterial disease or PAD market,” said David L. Martin, CSI president and chief executive officer. “Asahi peripheral guide wires address long, complex lesions above or below the knee, and complement the plaque removal capabilities of our Diamondback 360°. This agreement supports our mission to provide the more than 5,000 physicians and 2,000 hospitals treating PAD with comprehensive endovascular tools. In just a few minutes of treatment time the Diamondback 360° can keep patients walking and helps patients and their families avoid the high economic costs and trauma related to immobility and amputation.”

CSI’s flagship product is the Diamondback 360o® Peripheral Arterial Disease System, a minimally invasive catheter system for treating PAD. Between 8 million and 12 million Americans suffer from PAD, which is caused by the accumulation of plaque in leg or foot arteries, reducing blood flow. Symptoms include leg pain when walking or at rest, and PAD can lead to tissue loss and eventually limb amputation. The Diamondback 360o removes calcified and fibrous plaque and restores blood flow in vessels both below and above the knee.

“We are excited about the opportunity to work with CSI and its sales and marketing organization,” said Masahiko Miayata, president and chief executive officer of Asahi Intecc. “CSI is rapidly building a loyal customer base of physicians focused on treating PAD. We share the mutual goal of developing innovative technologies with the capabilities to address difficult PAD cases and improve patients’ lives.”

CSI will offer two Asahi 0.18 wire platforms: the Astato 30 and Treasure 12. The Astato 30 is a high-penetration guide wire specially designed to break through fibrous caps and calcium deposits, and treat long, complex lesions. The Treasure 12 has a one-piece core which provides exceptional control, superior torque performance and tactile feedback to the physician.

Jihad Mustapha, M.D., Metro Health Hospital, Grand Rapids, Mich., added, “I have used the Asahi wire in tough cases where other technologies failed. Asahi provides wires with a unique ability to transmit force applied outside of the body to the tip of the wire. When rotated, the Asahi Wires seem to turn at a 1:1 ratio; that is, they behave in a controllable way, giving me the ability to easily pass through the hard cap of a lesion. There is nothing else like these wires on the market.”

In addition to the Diamondback 360°, CSI offers a portfolio of supplemental PAD products, including its own Viper line. All products are available through the CSI national sales organization.

For additional information about Asahi Intecc Co., Ltd., visit the company’s Web site at: http://www.asahi-intecc.com

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing interventional treatment systems for vascular disease. The company’s Diamondback 360°® Peripheral Arterial Disease System treats calcified and fibrotic plaque in small and large vessels, and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. In August 2007, the U.S. FDA granted 510(k) clearance for the use of the Diamondback 360° as a therapy for PAD (peripheral arterial disease), and CSI commenced a U.S. product launch in September 2007. Since then, almost 600 hospitals across the United States have adopted the system, and more than 15,000 patients have been treated. For more information visit the company’s Web site at www.csi360.com.

Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From May 2024 to Jun 2024